drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate
drug_description
An antibody–drug conjugate targeting HER2 that delivers a topoisomerase I inhibitor (DXd). After HER2 binding and internalization, DXd is released to induce DNA damage and apoptosis; it also has a bystander effect and can inhibit HER2 signaling/mediate ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
trastuzumab deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2 and is internalized; a cleavable linker releases the DXd topoisomerase I inhibitor to induce DNA damage and apoptosis. The membrane-permeable payload produces a bystander effect, and the antibody component can inhibit HER2 signaling and mediate ADCC.
drug_name
Trastuzumab deruxtecan (T-DXd, DS-8201a)
nct_id_drug_ref
NCT06271837